Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib observational study in ES-SCLC patients with prior chemotherapy-induced grade 3/4 myelosuppression
ChiCTR2400087694Phase 4Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trilaciclib in small cell lung cancer (SCLC), sponsored by Tangdu Hospital. Primary endpoints: Incidence of severe neutropenia during the treatment cycle and Incidence of febrile neutropenia during the treatment cycle. Started Aug 2024; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400087694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087694.